Radiation Therapy For Oropharyngeal Squamous Cell Carcinoma

Concurrent high-dose intermittent cisplatin should be delivered to patients with stage IVA-B OPSCC receiving definitive RT. (Strong, High)

Concurrent cetuximab or carboplatin-fluorouracil should be delivered to patients with stage IVA-B OPSCC receiving definitive RT who are not medically fit for high-dose cisplatin. (Strong, High)

Concurrent weekly cisplatin may be delivered to patients with stage IVA-B OPSCC receiving definitive RT who are not medically fit for high-dose cisplatin, after a careful discussion of patient preferences and the limited prospective data supporting this regimen. (Conditional, Low)

Concurrent cetuximab should not be delivered in combination with chemotherapy to patients with stage IVA-B OPSCC receiving definitive RT. (Strong, High)

Intra-arterial chemotherapy should not be delivered to patients with stage IVA-B OPSCC receiving definitive RT. (Strong, High)

Concurrent systemic therapy should be delivered to patients with T3 N0-1 OPSCC receiving definitive RT. (Strong, Moderate)

After a careful discussion of patient preferences and the limited evidence supporting its use, concurrent systemic therapy may be delivered to patients with T1-T2 N1 OPSCC receiving definitive RT who are considered at particularly significant risk for locoregional recurrence. (Conditional, Low)

Concurrent systemic therapy should not be delivered to patients with stage I-II OPSCC receiving definitive RT. (Strong, Low)